As of today (2024-05-05), the Forward Annual Dividend Yield of Cancer Genetics is 0.00%.
As of today (2024-05-05), the Trailing Annual Dividend Yield of Cancer Genetics is 0.00%.
CGIX's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.505 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Cancer Genetics's Forward Dividend Yield %
For the Biotechnology subindustry, Cancer Genetics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cancer Genetics's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cancer Genetics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cancer Genetics's Forward Dividend Yield % falls into.
Cancer Genetics Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Cancer Genetics (NAS:CGIX) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Cancer Genetics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Cancer Genetics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cancer Genetics (Cancer Genetics) Business Description
Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CGIX has been successfully added to your